Controllability in Cancer Metabolic Networks According to Drug Targets as Driver Nodes

Networks are employed to represent many nonlinear complex systems in the real world. The topological aspects and relationships between the structure and function of biological networks have been widely studied in the past few decades. However dynamic and control features of complex networks have not been widely researched, in comparison to topological network features. In this study, we explore the relationship between network controllability, topological parameters, and network medicine (metabolic drug targets). Considering the assumption that targets of approved anticancer metabolic drugs are driver nodes (which control cancer metabolic networks), we have applied topological analysis to genome-scale metabolic models of 15 normal and corresponding cancer cell types. The results show that besides primary network parameters, more complex network metrics such as motifs and clusters may also be appropriate for controlling the systems providing the controllability relationship between topological parameters and drug targets. Consequently, this study reveals the possibilities of following a set of driver nodes in network clusters instead of considering them individually according to their centralities. This outcome suggests considering distributed control systems instead of nodal control for cancer metabolic networks, leading to a new strategy in the field of network medicine.

[1]  H. Nelson,et al.  Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. , 2001, The Journal of allergy and clinical immunology.

[2]  F. Garofalo,et al.  Controllability of complex networks via pinning. , 2007, Physical review. E, Statistical, nonlinear, and soft matter physics.

[3]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[4]  F. Fairman.  Introduction to dynamic systems: Theory, models and applications , 1979, Proceedings of the IEEE.

[5]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[6]  Lin He,et al.  Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study , 2011, PLoS Comput. Biol..

[7]  Igor Goryanin,et al.  Compartmentalization of the Edinburgh Human Metabolic Network , 2010, BMC Bioinformatics.

[8]  A. Ferrarini.  Some thoughts on the control of network systems , 2011 .

[9]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[10]  Jean-Jacques E. Slotine,et al.  On partial contraction analysis for coupled nonlinear oscillators , 2004, Biological Cybernetics.

[11]  Ina Koch,et al.  QuateXelero: An Accelerated Exact Network Motif Detection Algorithm , 2013, PloS one.

[12]  B. Palsson,et al.  Large-scale in silico modeling of metabolic interactions between cell types in the human brain , 2010, Nature Biotechnology.

[13]  Natapol Pornputtapong,et al.  Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT , 2012, PLoS Comput. Biol..

[14]  Tatsuya Akutsu,et al.  Dominating scale-free networks with variable scaling exponent: heterogeneous networks are not difficult to control , 2012 .

[15]  Albert-László Barabási,et al.  Controllability of complex networks , 2011, Nature.

[16]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[17]  Cristian R. Munteanu,et al.  MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. , 2011, Journal of proteome research.

[18]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[19]  J. Doyle,et al.  Bow Ties, Metabolism and Disease , 2022 .

[20]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Chung-Yen Lin,et al.  Hubba: hub objects analyzer—a framework of interactome hubs identification for network biology , 2008, Nucleic Acids Res..

[22]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[23]  M. di Bernardo,et al.  How to Turn a Genetic Circuit into a Synthetic Tunable Oscillator, or a Bistable Switch , 2009, PloS one.

[24]  P. Karp,et al.  Computational prediction of human metabolic pathways from the complete human genome , 2004, Genome Biology.

[25]  S. Shen-Orr,et al.  Network motifs in the transcriptional regulation network of Escherichia coli , 2002, Nature Genetics.

[26]  Eric K. Gupta,et al.  Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. , 2002, Heart disease.

[27]  T. Seyfried,et al.  Cancer as a metabolic disease , 2010, Nutrition & metabolism.

[28]  Falk Schreiber,et al.  Analysis of Biological Networks , 2008 .

[29]  Krin A. Kay,et al.  The implications of human metabolic network topology for disease comorbidity , 2008, Proceedings of the National Academy of Sciences.

[30]  Tamás Vicsek,et al.  Controlling edge dynamics in complex networks , 2011, Nature Physics.

[31]  S. Horvath,et al.  Variations in DNA elucidate molecular networks that cause disease , 2008, Nature.

[32]  Aarash Bordbar,et al.  iAB-RBC-283: A proteomically derived knowledge-base of erythrocyte metabolism that can be used to simulate its physiological and patho-physiological states , 2011, BMC Systems Biology.

[33]  B. Palsson,et al.  Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions , 2010, Molecular systems biology.

[34]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[35]  Philip E. Bourne,et al.  Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..

[36]  Markus J. Herrgård,et al.  Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.

[37]  B. Snel,et al.  Predicting disease genes using protein–protein interactions , 2006, Journal of Medical Genetics.

[38]  Adam M. Feist,et al.  The growing scope of applications of genome-scale metabolic reconstructions using Escherichia coli , 2008, Nature Biotechnology.

[39]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..

[40]  Soumen Roy,et al.  Key to Network Controllability , 2012, ArXiv.

[41]  T. Murayama,et al.  Distributed Control System , 1991, Fifth International Conference on Advanced Robotics 'Robots in Unstructured Environments.

[42]  Adilson E. Motter,et al.  Slave nodes and the controllability of metabolic networks , 2009, 0911.5518.

[43]  E. Ruppin,et al.  Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism , 2010, Molecular systems biology.

[44]  Jens Nielsen,et al.  Codon usage variability determines the correlation between proteome and transcriptome fold changes , 2011, BMC Systems Biology.

[45]  Albert-László Barabási,et al.  Control Centrality and Hierarchical Structure in Complex Networks , 2012, PloS one.

[46]  V. Gladyshev,et al.  Evolution of selenium utilization traits , 2005, Genome Biology.

[47]  Shilpa Chakravartula,et al.  Complex Networks: Structure and Dynamics , 2014 .

[48]  Sahar Asadi,et al.  Kavosh: a new algorithm for finding network motifs , 2009, BMC Bioinformatics.

[49]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[50]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[51]  Alex Arenas,et al.  Paths to synchronization on complex networks. , 2006, Physical review letters.

[52]  Weiping Li,et al.  Applied Nonlinear Control , 1991 .

[53]  Guido Caldarelli,et al.  Scale-Free Networks , 2007 .

[54]  S. Strogatz.  Exploring complex networks , 2001, Nature.

[55]  C. Gille,et al.  HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology , 2010, Molecular systems biology.

[56]  I. Nookaew,et al.  Fifteen years of large scale metabolic modeling of yeast: developments and impacts. , 2012, Biotechnology advances.

[57]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[58]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[59]  B. Palsson,et al.  A protocol for generating a high-quality genome-scale metabolic reconstruction , 2010 .

[60]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[61]  Kounosuke Watabe,et al.  Metabolic genes in cancer: their roles in tumor progression and clinical implications. , 2010, Biochimica et biophysica acta.

[62]  Albert-László Barabási,et al.  Evolution of Networks: From Biological Nets to the Internet and WWW , 2004 .

[63]  Richard Morphy,et al.  Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.

[64]  Gary D. Bader,et al.  An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.

[65]  O. Reséndis-Antonio,et al.  Modeling Core Metabolism in Cancer Cells: Surveying the Topology Underlying the Warburg Effect , 2010, PloS one.